For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Barcelona 8025

0 studies enrolling now · 83 studies all time

What they study most

Acute Coronary Syndrome, Adenocarcinoma of the Gastroesophageal Junction, Alzheimer's Disease, Autoimmune Disease, Biliary Tract Cancer, Brain Metastases, Breast Cancer, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Cardiovascular Disease, Chronic Kidney Disease

Studies at this site

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms — Running, not enrolling
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer — Running, not enrolling
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — Running, not enrolling
A Study of LY3039478 in Participants With Advanced Cancer — Completed
A Study in Recurrent Glioblastoma (GB) — Completed
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors — Stopped early
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer — Completed
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma — Completed
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer — Completed
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer — Completed
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms — Completed
Evaluation of Galcanezumab in the Prevention of Chronic Migraine — Completed
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer — Completed
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer — Completed
A Study of LY2157299 in Participants With Hepatocellular Carcinoma — Completed
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain — Completed
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC — Completed
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) — Completed
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer — Completed
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study — Completed
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer — Completed
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes — Completed
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread — Completed
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body — Stopped early
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma — Completed
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension — Completed
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
A Study of Tadalafil for Duchenne Muscular Dystrophy — Stopped early
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) — Completed
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease — Stopped early
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) — Completed
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy — Completed
A Study in Second Line Metastatic Colorectal Cancer — Completed
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture — Completed
VERtebral Fracture Treatment Comparisons in Osteoporotic Women — Completed
A Study in Non-Small Cell Lung Cancer — Completed
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) — Completed
A Study in Moderate to Severe Rheumatoid Arthritis — Completed
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma — Completed
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes — Completed
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma — Completed
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer — Completed
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis — Completed
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) — Completed
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus — Completed
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma — Stopped early
An Open Label Study for Participants With Rheumatoid Arthritis — Stopped early
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement — Completed
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease — Stopped early